GLP1R and obesity disorder: Nevertheless, this study is timely since the development of various anti‐obesity interventions, such as glucagon‐like peptide 1 (GLP‐1) receptor agonists and related compounds, has allowed patients with obesity to reduce their body weight by over 10% [41].